Symptom clusters in cancer patients and their relation to EGFR ligand modulation of the circadian axis

Journal of Supportive Oncology

Volumn 5, Issue 4, 2007, Pages 167-174

  Rich, Tyvin A ^a  

^a UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; GEFITINIB; HYDROCORTISONE; INTERLEUKIN 1; INTERLEUKIN 10; INTERLEUKIN 2; INTERLEUKIN 6; MONOCLONAL ANTIBODY; NEU DIFFERENTIATION FACTOR; PROTEIN TYROSINE KINASE INHIBITOR; TRANSFORMING GROWTH FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN; LIGAND;

ACTIMETRY; ANOREXIA; ANTERIOR HYPOTHALAMUS; BIOLOGICAL RHYTHM; BREAST CANCER; CANCER; CANCER PATIENT; CHRONOBIOLOGY; CIRCADIAN RHYTHM; COLON CANCER; COLORECTAL CANCER; FATIGUE; GENE OVEREXPRESSION; HEAD AND NECK CANCER; HUMAN; HYDROCORTISONE BLOOD LEVEL; HYPOTHALAMUS; LUNG CANCER; LUNG NON SMALL CELL CANCER; NONHUMAN; PANCREAS CANCER; PROGNOSIS; QUALITY OF LIFE; RECTUM CANCER; REVIEW; SIGNAL TRANSDUCTION; SLEEP DISORDER; SOMNOLENCE; SUPRACHIASMATIC NUCLEUS; THALAMUS DORSOMEDIAL NUCLEUS; ANIMAL; GENETICS; METABOLISM; NEOPLASM; PHYSIOLOGY;

ANIMALS; CIRCADIAN RHYTHM; HUMANS; HYDROCORTISONE; HYPOTHALAMUS; LIGANDS; NEOPLASMS; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 34250192263     PISSN: 15446794     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (87)

1. Cleeland CS, Mendoza TR, Wang XS, et al. Assessing symptom distress in cancer patients: the M.D. Anderson Symptom Inventory. Cancer 2000;89:1634-1646. [11013380]
2. Cleeland CS, Bennett GJ, Dantzer R, et al. Are the symptoms of cancer and cancer treatment due to a shared biologic mechanism? A cytokine-immunologic model of cancer symptoms. Cancer 2003;97:2919-2925. [12767108]
3. Dantzer R. Cytokine-induced sickness behavior: mechanisms and implications. Ann N Y Acad Sci 2001;933:222-234. [12000023]
4. Kelley KW, Bluthe RM, Dantzer R, et al. Cytokine-induced sickness behavior. Brain Behav Immun 2003;17(suppl 1):S112-S118. [12615196]
5. Ebrahimi B, Tucker SL, Li D, Abbruzzese JL, Kurzrock R. Cytokines in pancreatic carcinoma: correlation with phenotypic characteristics and prognosis. Cancer 2004;101:2727-2736 [15526319]
6. Kurzrock R. Cytokine deregulation in hematological malignancies: clinical and biological implications. Clin Cancer Res 1997;3:2581-2584. [9815659]
7. Kurzrock R. Cytokine deregulation in cancer. Biomed Pharmacother 2001;55:543-547. [11769963]
8. Malik UR, Makower DF, Wadler S. Interferon-mediated fatigue. Cancer 2001;92(6 suppl):1664-1668. [11598884]
9. Capuron L, Ravaud A, Dantzer R. Early depressive symptoms in cancer patients receiving interleukin 2 and/or interferon alfa-2b therapy. J Clin Oncol 2000;18:2143-2151. [10811680]
10. Capuron L, Ravaud A, Gualde N, et al. Association between immune activation and early depressive symptoms in cancer patients treated with interleukin-2-based therapy. Psychoneuroendocrinology 2001;26:797-808. [11585680]
11. Musselman DL, Miller AH, Porter MR, et al. Higher than normal plasma interleukin-6 concentrations in cancer patients with depression: preliminary findings. Am J Psychiatry 2001;158:1252-1257. [11481159]
12. Lutgendorf SK, Johnsen EL, Cooper B, et al. Vascular endothelial growth factor and social support in patients with ovarian carcinoma. Cancer 2002;95:808-815. [12209725]
13. Snodgrass-Belt P, Gilbert JL, Davis FC. Central administration of transforming growth factor-alpha and neuregulin-1 suppress active behaviors and cause weight loss in hamsters. Brain Res 2005;1038:171-182. [15757633]
14. Kramer A, Yang FC, Snodgrass P, et al. Regulation of daily locomotor activity and sleep by hypothalamic EGF receptor signaling. Science 2001;294:2511-2515. [11752569]
15. Kramer A, Yang FC, Kraves S, Weitz CJ. A screen for secreted factors of the suprachiasmatic nucleus. Methods Enzymol 2005;393:645-663. [15817317]
16. Saper CB, Cano G, Scammell TE. Homeostatic, circadian, and emotional regulation of sleep. J Comp Neurol 2005;493:92-98. [16254994]
17. Saper CB, Scammell TE, Lu J. Hypothalamic regulation of sleep and circadian rhythms. Nature 2005;437:1257-1263. [16251950]
18. Saper CB, Lu J, Chou TC, Gooley J. The hypothalamic integrator for circadian rhythms. Trends Neurosci 2005;28:152-157. [15749169]
19. Chou TC, Scammell TE, Gooley JJ, et al. Critical role of dorsomedial hypothalamic nucleus in a wide range of behavioral circadian rhythms. J Neurosci 2003;23:10691-10702. [14627654]
20. Hastings MH, Reddy AB, Maywood ES. A clock-work web: circadian timing in brain and periphery, in health and disease. Nat Rev Neurosci 2003;4:649-661. [12894240]
21. Reppert SM, Weaver DR. Coordination of circadian timing in mammals. Nature 2002;418:935-941. [12198538]
22. Arendt J. Melatonin: characteristics, concerns, and prospects. J Biol Rhythms 2005;20:291-303. [16077149]
23. Arendt J. Melatonin and human rhythms. Chronobiol Int 2006;23:21-37. [16687277]
24. Sehgal A, ed. Molecular Biology of Circadian Rhythms. Hoboken, NJ: John Wiley & Sons; 2004.
25. Hastings MH, Herzog ED. Clock genes, oscillators, and cellular networks in the suprachiasmatic nuclei. J Biol Rhythms 2004;19:400-413. [15534320]
26. Herzog ED, Tosini G. The mammalian circadian clock shop. Semin Cell Dev Biol 2001;12:295-303. [11463214]
27. Weaver DR. The suprachiasmatic nucleus: a 25-year retrospective. J Biol Rhythms 1998;13:100-112. [9554572]
28. Lee HS, Billings HJ, Lehman MN. The suprachiasmatic nucleus: a clock of multiple components. J Biol Rhythms 2003;18:435-449. [14667145]
29. Aschoff J, Wever R. Human circadian rhythms: a multioscillatory system. Fed Proc 1976;35:236-232. [786739]
30. Kennaway DJ, Van Dorp CF. Free-running rhythms of melatonin, cortisol, electrolytes, and sleep in humans in Antarctica. Am J Physiol 1991;260: R1137-R1144. [2058741]
31. Perreau-Lenz S, Pevet P, Buijs RM, Kalsbeek A. The biological clock: the bodyguard of temporal homeostasis. Chronobiol Int 2004;21:1-25. [15129821]
32. Viswanathan N, Davis FC. Suprachiasmatic nucleus grafts restore circadian function in aged hamsters. Brain Res 1995;686:10-16. [7583260]
33. Guo H, Brewer JM, Lehman MN, Bittman EL. Suprachiasmatic regulation of circadian rhythms of gene expression in hamster peripheral organs: effects of transplanting the pacemaker. J Neurosci 2006;26:6406-6412. [16775127]
34. Ralph MR, Foster RG, Davis FC, Menaker M. Transplanted suprachiasmatic nucleus determines circadian period. Science 1990;247:975-978. [2305266]
35. Mistlberger RE. Circadian regulation of sleep in mammals: role of the suprachiasmatic nucleus. Brain Res Brain Res Rev 2005;49:429-454. [16269313]
36. Masumoto KH, Nagano M, Takashima N, et al. Distinct localization of prokineticin 2 and prokineticin receptor 2 mRNAs in the rat suprachiasmatic nucleus. Eur J Neurosci 2006;23:2959-2970. [16819985]
37. Zhou QY, Cheng MY. Prokineticin 2 and circadian clock output. FEBS J 2005;272:5703-5709. [16279936]
38. Cheng MY, Bittman EL, Hattar S, Zhou QY. Regulation of prokineticin 2 expression by light and the circadian clock. BMC Neurosci 2005;6:17. [15762991]
39. Cheng MY, Bullock CM, Li C, et al. Prokineticin 2 transmits the behavioral circadian rhythm of the suprachiasmatic nucleus. Nature 2002;417:405-410. [12024206]
40. Kraves S, Weitz CJ. A role for cardiotrophin-like cytokine in the circadian control of mammalian locomotor activity. Nat Neurosci 2006;9:212-219. [16429135]
41. Lu J, Zhang YH, Chou TC, et al. Contrasting effects of ibotenate lesions of the paraventricular nucleus and subparaventricular zone on sleep-wake cycle and temperature regulation. J Neurosci 2001;21:4864-4874. [11425913]
42. Von Economo C. Sleep as a problem of localization. J Nerv Ment Dis 1930;71:249-259.
43. Balsalobre A. Clock genes in mammalian peripheral tissues. Cell Tissue Res 2002;309:193-199. [12111549]
44. Piggins HD. Human clock genes. Ann Med 2002;34:394-400. [12452483]
45. Sato TK, Panda S, Kay SA, Hogenesch JB. DNA arrays: applications and implications for circadian biology. J Biol Rhythms 2003;18:96-105. [12693865]
46. Williams DL, Schwartz MW. Out of synch: clock mutation causes obesity in mice. Cell Metab 2005;1:355-356. [16054082]
47. Turek FW, Joshu C, Kohsaka A, et al. Obesity and metabolic syndrome in circadian Clock mutant mice. Science 2005;308:1043-1045. [15845877]
48. Easton A, Arbuzova J, Turek FW. The circadian Clock mutation increases exploratory activity and escape-seeking behavior. Genes Brain Behav 2003;2:11-19. [12882315]
49. Stephan FK. Broken circadian clocks: a clock gene mutation and entrainment by feeding. Am J Physiol Regul Integr Comp Physiol 2003;285:R32-R33. [12793992]
50. Wijnen H, Boothroyd C, Young MW, Claridge-Chang A. Molecular genetics of timing in intrinsic circadian rhythm sleep disorders. Ann Med 2002;34:386-393. [12452482]
51. Lowrey PL, Takahashi JS. Mammalian circadian biology: elucidating genome-wide levels of temporal organization. Annu Rev Genomics Hum Genet 2004;5:407-441. [15485355]
52. Fu L, Pelicano H, Liu J, Huang P, Lee C. The circadian gene Period2 plays an important role in tumor suppression and DNA damage response in vivo. Cell 2002;111:41-50. [12372299]
53. Fu L, Lee CC. The circadian clock: pacemaker and tumour suppressor. Nat Rev Cancer 2003;3:350-361. [12724733]
54. Hirayama J, Cardone L, Doi M, Sassone-Corsi P. Common pathways in circadian and cell cycle clocks: light-dependent activation of Fos/AP-1 in zebrafish controls CRY-1a and WEE-1. PNAS 2005;102:10194-10199. [16000406]
55. Granda TG, Liu XH, Smaaland R, et al. Circadian regulation of cell cycle and apoptosis proteins in mouse bone marrow and tumor. FASEB J 2004;19:304-306. [15545298]
56. Bjarnason GA, Jordan RC, Sothern RB. Circadian variation in the expression of cell-cycle proteins in human oral epithelium. Am J Pathol 1999;154:613-622. [10027418]
57. Bjarnason GA, Jordan R. Circadian variation of cell proliferation and cell cycle protein expression in man: clinical implications. Prog Cell Cycle Res 2000;4:193-206. [10740826]
58. Bjarnason GA, Jordan RC, Wood PA, et al. Circadian expression of clock genes in human oral mucosa and skin: association with specific cell-cycle phases. Am J Pathol 2001;158:1793-1801. [11337377]
59. Mormont MC, Levi F. Circadian-system alterations during cancer processes: a review. Int J Cancer 1997;70:241-247. [9009166]
60. Levi F. Circadian chronotherapy for human cancers. Lancet Oncol 2001;2:307-315. [11905786]
61. Sephton SE, Sapolsky RM, Kraemer HC, Spiegel D. Diurnal cortisol rhythm as a predictor of breast cancer survival. J Natl Cancer Inst 2000;92:994-1000. [10861311]
62. Abercrombie HC, Giese-Davis J, Sephton S, et al. Flattened cortisol rhythms in metastatic breast cancer patients. Psychoneuroendocrinology 2004;29:1082-1092. [15219660]
63. Blake-Mortimer JS, Sephton SE, Carlson RW, Stites D, Spiegel D. Cytotoxic T lymphocyte count and survival time in women with metastatic breast cancer. Breast J 2004;10:195-199. [15125744]
64. Spiegel D. Effects of psychotherapy on cancer survival. Nat Rev Cancer 2002;2:383-389. [12044014]
65. Mormont MC, Hecquet B, Bogdan A, et al. Non-invasive estimation of the circadian rhythm in serum cortisol in patients with ovarian or colorectal cancer. Int J Cancer 1998;78:421-424. [9797128]
66. Mormont MC, Waterhouse J, Bleuzen P, et al. Marked 24-h rest/activity rhythms are associated with better quality of life, better response, and longer survival in patients with metastatic colorectal cancer and good performance status. Clin Cancer Res 2000;6:3038-3045. [10955782]
67. Mormont MC, Waterhouse J. Contribution of the rest-activity circadian rhythm to quality of life in cancer patients. Chronobiol Int 2002;19:313-323. [11962684]
68. Mormont MC, Langouet AM, Claustrat B, et al. Marker rhythms of circadian system function: a study of patients with metastatic colorectal cancer and good performance status. Chronobiol Int 2002;19:141-155. [11962672]
69. Ancoli-Israel S, Cole R, Alessi C, et al. The role of actigraphy in the study of sleep and circadian rhythms. Sleep 2003;26:342-392. [12749557]
70. Levin RD, Daehler MA, Grutsch JF, et al. Circadian function in patients with advanced non-small-cell lung cancer. Br J Cancer 2005;93:1202-1208. [16265345]
71. Innominato PF, Focan C, Bjarnason GA, et al, for the EORTC Chronotherapy Group. Quality of life (QOL) correlates with the rest/activity circadian rhythm (RAR) in patients (pts) with metastatic colorectal cancer (MCC) on first line chemotherapy with 5-fluorouracil, leucovorin and oxaliplatin: an international multicenter study (EORTC 05963). J Clin Oncol 2005;23(16S):8029.
72. Yarden Y. The EGFR family and its ligands in human cancer: signaling mechanisms and therapeutic opportunities. Eur J Cancer 2001;37(suppl 4):S3-S8. [11597398]
73. Holbro T, Civenni G, Hynes NE. The ErbB receptors and their role in cancer progression. Exp Cell Res 2003;284:99-110. [12648469]
74. Holbro T, Hynes NE. ErbB receptors: directing key signaling networks throughout life. Annu Rev Pharmacol Toxicol 2004;44:195-217. [14744244]
75. Arteaga C. Targeting HER1/EGFR: a molecular approach to cancer therapy. Semin Oncol 2003;30(suppl7):3-14. [12840796]
76. Ettinger DS. Clinical implications of EGFR expression in the development and progression of solid tumors: focus on non-small cell lung cancer. Oncologist 2006;11:358-373. [16614231]
77. Majumdar AP. Therapeutic potential of EGFR-related protein, a universal EGFR family antagonist. Future Oncol 2005;1:235-245. [16555995]
78. Todd R, Wong DT. Epidermal growth factor receptor (EGFR) biology and human oral cancer. Histol Histopathol 1999;14:491-500. [10212811]
79. Xu H, Yu Y, Marciniak D, et al. Epidermal growth factor receptor (EGFR)-related protein inhibits multiple members of the EGFR family in colon and breast cancer cells. Mol Cancer Ther 2005;4:435-442. [15767552]
80. Ishikawa N, Daigo Y, Takano A, et al. Increases of amphiregulin and transforming growth factor-alpha in serum as predictors of poor response to gefitinib among patients with advanced non-small cell lung cancers. Cancer Res 2005;65:9176-9184. [16230376]
81. Korc M. Role of growth factors in pancreatic cancer. Surg Oncol Clin N Am 1998;7:25-41. [9443985]
82. Yamanaka Y, Friess H, Kobrin MS, et al. Coexpression of epidermal growth factor receptor and ligands in human pancreatic cancer is associated with enhanced tumor aggressiveness. Anticancer Res 1993;13:565-569. [8317885]
83. Rich T, Innominato PF, Boerner J, et al. Elevated serum cytokines correlated with altered behavior, serum cortisol rhythm, and dampened 24-hour rest-activity patterns in patients with metastatic colorectal cancer. Clin Cancer Res 2005;11:1757-1764. [15755997]
84. Cella D. Impact of ZD1839 on non-small cell lung cancer-related symptoms as measured by the functional assessment of cancer therapy-lung scale. Semin Oncol 2003;30(suppl 1):39-48. [12644983]
85. Cella D, Herbst RS, Lynch TJ, et al. Clinically meaningful improvement in symptoms and quality of life for patients with non-small-cell lung cancer receiving gefitinib in a randomized controlled trial. J Clin Oncol 2005;23:2946-2954. [15699477]
86. Vgontzas AN, Zoumakis M, Bixler EO, et al. Impaired nighttime sleep in healthy old versus young adults is associated with elevated plasma interleukin-6 and cortisol levels: physiologic and therapeutic implications. J Clin Endocrinol Metab 2003;88:2087-2095. [12727959]
87. Vgontzas AN, Bixler EO, Lin HM, et al. IL-6 and its circadian secretion in humans. Neuroimmunomodulation 2005;12:131-140. [15905620]